Lars Bo Nielsen (MD, PhD, DMSc) serves as Director General of The Danish Medicines Agency (DKMA) since 2021. In the EU regulatory network, he is a member of the EMA Management Board and member of the HMA Management Group. Before joining DKMA his occupations from 2004-2021 included clinical and research activities at Rigshospitalet, Copenhagen and Danish universities, more specifically University of Copenhagen and Aarhus University. From 2017-2021 he served as Dean and Professor at HEALTH, Aarhus University. From 2007-2017 as Professor Functional genomics in biomedicine, Department of Biomedical Sciences, and from 2012-2017 as Head of Department of Clinical Medicine, both at University of Copenhagen. From 2004-2017 alongside with his work at the University of Copenhagen, he served as consultant at The Department of Clinical Biochemistry, Rigshospitalet, Copenhagen. From 2010-2015 as Head of the Department.

Dr. Seogyoun Kang serves as Director General of Pharmaceutical Safety Bureau at the Ministry of Food and Drug Safety, Republic of Korea since May 2021. Dr. Kang is responsible for overall pharmaceutical policy and management, pharmacovigilance, pharmaceutical approval and patent management, nonclinical/clinical study policy, narcotics policy and management. He was in charge of several divisions as Director including biologics, risk information, food and consumer safety, narcotics policy and biopharmaceutical policy. Prior to his current position, he served as Director General of Biopharmaceuticals and Herbal Medicine bureau in 2019 and as head of Post Covid-19 task force team. He earned a PhD in pharmacy from the Chung-Ang University, Republic of Korea, in 1998.

Mr Hiiti Sillo is the Unit Head, Regulation and Safety within the WHO Department of Regulation and Prequalification. In this role, he coordinates WHO strategies for strengthening national and regional regulatory systems as well as promoting regulatory harmonization, networking, convergence, work-sharing and reliance including through the implementation of WHO Listed Authorities Initiative. He was previously the Team Lead, Regulatory Systems Strengthening, Regulation and Safety Unit. Before joining WHO in January 2018, he was the Director General of the Tanzania Food and Drugs Authority (TFDA). In this capacity, he was one of the pioneers for the launch of the African Medicines Regulatory Harmonization (AMRH) Initiative, a strong foundation for the establishment and operationalization of the African Medicines Agency (AMA). Mr Sillo is a Pharmacist and holds an MSc in Medicines Control and Pharmaceutical Services, University of Bradford, UK.

Mr. Barra, President-Director of Anvisa, graduated in Medicine from Technical Educational Foundation Souza Marques in 1986 and had his residency in Vascular and Endovascular surgery done at Marcílio Dias Naval Hospital (HNMD) in Rio de Janeiro. MBA in Health Services Administration at Federal University of Rio de Janeiro, in 2012. In his last year in Medical College, he worked as a scientific advisor in a group of several medical publications. In 1987 joined Brazilian Navy as a medical officer. In 2015 he was promoted to the rank of Rear Admiral, the second highest rank in the Medical Corps. Throughout his 32 years long naval career, Admiral Barra treated the patients of the nuclear accident in Goiania (1987), served on two ships as a doctor (1988 e 1994), was Deputy officer of the Health Department in a Marine Corps unit (1995-1997), medical officer of Antarctic Station CDR Ferraz in Antarctic area (1998), head of vascular surgery clinics of HNMD (2002-2007), commanding officer of São Pedro da Aldeia Medical Naval unit (2008-2009), Vice-Director of Navy’s Health Directorate (2010-2011), Vice-Director of HNMD (2013-2014). As Admiral, he was the commanding officer of the Navy’s Health Trials Center (2015-2016) and the commanding officer Navy’s Medical Assistance Center (2017-2018). Retired from the Navy in February of 2019, was approved by the Brazilian Senate to the position of Anvisa’s Director in July of the same year. He was later confirmed as President-Director in October 2020. In March 2023, was appointed by the Executive Committee, and the Plenary of the International Coalition of Medicine Regulatory Authorities (ICMRA) as second vice-chair.